Generation Bio (GBIO) - Total Stockholders' Equity

Public company logo of Generation Bio Co (GBIO)

Generation Bio Co. (GBIO) leads the development of cell-free gene delivery systems, granting the company significant pricing power over its therapies. However, a lack of profitability and the costs associated with manufacturing plants create serious financial challenges. The current metric stands at 0.05. Market price action on GURU.Markets reflects the risk of secondary offerings and potential failures in early-stage testing of new platforms.

Generation Bio Co (GBIO) - Company Book Value from 07/04/2022 to 02/21/2026

Analytical breakdowns for Generation Bio Corp (GBIO)

- price and consensus price forecast:
Market Chart Generation Bio Co.|GBIO - Price Target Chart
- market capitalization data:
Market Value Generation Bio Co|GBIO - Enterprise Value
- book capitalization data:
Equity per Share Generation Bio|GBIO - Company Book Value|Capitalization to Book Value Ratio generationbio.com|GBIO - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Generation Bio Co.|GBIO - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Generation Bio Co.|GBIO - Company Aggregate Debts|Debts to Book Value Generation Bio Co
Summary company analysis:Generation Bio - GBIO
Mass-produced product of Generation Bio Co.

Book value reflects the value of net assets, representing the difference between all assets and liabilities to assess the internal stability of the business. By analyzing the book value of Generation Bio Co. (GBIO), an investor sees the financial foundation supporting the implementation of eco-friendly synthesis methods and strict bioethical standards, confirming the issuer's ability to develop safe genetic technologies without critical dependence on external borrowing.

Main competitors

TEM: Book Valuation of Business|Company Book Value QGEN|ionispharma.com (IONS) - Total Stockholders' Equity|Book Capitalization Repligen (RGEN)|Accounting Capitalization RNA|Company Book Value CRISPR Therapeutics Corp CRSP|Accounting Capitalization GeneDx Corp (WGS)|Book Capitalization RARE (Ultragenyx Pharmaceutical)|Book Capitalization beamtx.com BEAM|Book Capitalization SRPT|TWST - Book Value of Business|Book Capitalization TXG|NTLA (Intellia Corp) - Total Stockholders' Equity|Company Book Value Stoke Therapeutics (STOK)|Accounting Capitalization biolifesolutions.com|Wave Life Sciences Ltd. - Book Capitalization|Total Stockholders' Equity MAZE (Maze Therapeutics, Inc.)|Company Book Value Sionna Pharma|Accounting Value of Company Prime Medicine Bio PRME|Taysha Gene Therapies - Book Capitalization|uniqure.com (QURE) - Book Capitalization|MGTX - Company Net Assets|REGENXBIO Inc (RGNX) - Total Net Assets|SLDB: Book Capitalization|Book Valuation of Business OCGN|Pacific Biosciences - Company Book Value|Total Stockholders' Equity BNTC (benitec.com)|DSGN - Company Book Value|RCKT - Accounting Capitalization|Company Net Assets 4D Molecular Therapeutics Inc (FDMT)|LXEO - Accounting Value of Company|korrobio.com (KRRO) - Book Capitalization|editasmedicine.com (EDIT) - Company Book Value|SLN: Book Capitalization|Book Valuation of Business PRQR|Codexis, Inc. - Company Book Value|Total Stockholders' Equity Sangamo BioSciences SGMO|Company Net Assets Nautilus Bio|Accounting Value of Company metagenomi.co MGX|DTIL: Book Capitalization|BOLD: Company Net Assets|Company Book Value XCUR|Total Stockholders' Equity Imunon|PHIO: Company Net Assets|Book Valuation of Business Mustang Bio Corp|RNAZ: Book Capitalization|Book Value of Business bionanogenomics.com (BNGO)|Book Capitalization Applied DNA APDN|Company Book Value bluebird bio, Inc BLUE|Book Capitalization IPA (ImmunoPrecise)|OMGA: Book Valuation of Business|Company Book Value OMIC|Regulus Therapeutics, Inc. (RGLS) - Total Stockholders' Equity|Book Capitalization Syros (SYRS)|Accounting Capitalization TBIO|Company Book Value TRACON Pharmaceuticals TCON|Accounting Capitalization unitybiotechnology.com (UBX)